BioMarin to acquire Repligen HDAC inhibitors

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will acquire a portfolio of histone deacetylase (HDAC) inhibitors and related IP from Repligen Corp. (NASDAQ:RGEN). The portfolio includes undisclosed oral small molecules in preclinical development for Friedreich's ataxia. Repligen will receive $2 million up front and is eligible for up to $160 million in milestones, plus royalties. In August 2012, Repligen said it would focus its resources on expanding its bioprocessing business (see BioCentury Extra, Aug. 2, 2012). ...